Key result
Folate supplementation (5 mg/day) for 12 weeks significantly reduced maximum left carotid intima-media thickness compared to placebo (-0.05 vs. +0.02 mm; P=0.01) in patients with metabolic syndrome.
Why the study?
Does folate supplementation improve carotid intima-media thickness and metabolic status in overweight patients with metabolic syndrome, type 2 diabetes, and coronary heart disease?
RCT (n=60)
Double-blind
Randomly divided
Does folate supplementation improve carotid intima-media thickness and metabolic status in overweight patients with metabolic syndrome, type 2 diabetes, and coronary heart disease?
Absolute Event Rate: -0.05% vs 0.02%
p-value: p=0.01
Folate supplementation at 5 mg/day for 12 weeks significantly improves carotid intima-media thickness and metabolic markers in overweight patients with metabolic syndrome, diabetes, and coronary heart disease.
Folate may slow subclinical carotid atherosclerosis in metabolic syndrome; extends B-vitamin RCT evidence to imaging surrogates.
BACKGROUND: This study was carried out to evaluate the effects of folate supplementation on carotid intima-media thickness (CIMT) and metabolic status among patients with metabolic syndrome (MetS). METHODS: This randomized, double-blind, placebo-controlled trial was conducted among 60 patients with type 2 diabetes mellitus and coronary heart disease. They were all overweight in the age range 40-85 years. Participants were randomly divided into 2 groups: group A (n = 30) received 5 mg folate supplements and group B (n = 30) received placebo for 12 weeks. RESULTS: Folate supplementation resulted in a significant reduction in maximum levels of left CIMT (-0.05 ± 0.13 vs. +0.02 ± 0.11 mm, p = 0.01) compared with the placebo. Changes in fasting plasma glucose (-2.2 ± 37.5 vs. +30.2 ± 65.8 mg/dl, p = 0.02), serum insulin concentration (-2.0 ± 10.7 vs. +3.0 ± 7.6 µIU/ml, p = 0.04) and homeostasis of assessment-estimated insulin resistance (-0.6 ± 2.3 vs. +0.9 ± 2.3, p = 0.01) in supplemented patients were significantly different from those of patients in the placebo group. Changes in serum triglycerides (p = 0.04), high-density lipoprotein-cholesterol (p = 0.001), high sensitivity C-reactive protein (p = 0.01) and plasma nitric oxide concentrations (p < 0.001) were significantly different between the supplemented patients and placebo group. CONCLUSIONS: Overall, 5 mg/day folate supplementation for 12 weeks among patients with MetS had beneficial effects on CIMT and the metabolic status.
No takes yet. Share an insight, caveat, or question.
Talari et al. (2016) conducted an RCT in Metabolic syndrome (n=60). Folate vs. Placebo was evaluated on Maximum levels of left carotid intima-media thickness (CIMT) (p=0.01). Folate supplementation (5 mg/day) for 12 weeks significantly reduced maximum left carotid intima-media thickness compared to placebo (-0.05 vs. +0.02 mm; P=0.01) in patients with metabolic syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: